<DOC>
	<DOCNO>NCT00276276</DOCNO>
	<brief_summary>The purpose study find give oral HYCAMTIN patient relapse small cell lung cancer benefit . The study compare long patient live give therapy make feel good ( active symptom control ) length time patient live also receive oral HYCAMTIN .</brief_summary>
	<brief_title>Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Received one prior chemotherapy regimen . Documented partial complete response firstline therapy . Documented relapse limited extensive SCLC least 45 day cessation firstline chemotherapy . Not consider suitable intravenous chemotherapy . Considered adequate bone marrow reserve . Performance Status 0 , 1 2 . Pregnant lactating . Received one prior regimen chemotherapy . Uncontrolled vomiting . Brain metastasis . Active uncontrolled infection . Received previous treatment HYCAMTIN . Received investigational product within 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>relapse</keyword>
	<keyword>lung cancer</keyword>
	<keyword>resistant</keyword>
	<keyword>small cel</keyword>
	<keyword>topotecan ( HYCAMTIN )</keyword>
</DOC>